Long-acting drug delivery has emerged as the novel and advanced drug delivery system which manipulates the dosing regimen of the drug in the body in order to sustain its therapeutic level. Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases.
The long-acting delivery of drug candidates confers several advantages, such as improved patient compliance, reduced dosage requirement, better medication adherence, decrease in failure risk due to inconsistent usage and more convenience to patients. In addition, long-acting drug delivery formulations can improve the chemical stability, solubility and polymorphic transformation issues of the active pharmaceutical ingredients.
Lately, many technologies are being explored to develop long-acting drugs in various dosage formats, such as long-acting injectables, depot injections, implantable devices and combination products. The long-acting drug delivery technologies have come a long way with the inclusion of liposomes, microspheres and polymers for the fabrication of biodegradable and biocompatible delivery systems.
Apart from this, the interdependency of drug, excipient and release environment plays a crucial role to decide the release kinetics of the drug. Long-acting formulations are more patient compliant, in terms of sharp reduction in the dosing regimen. These drugs are administered infrequently (ranging from once weekly to yearly) owing to the prolonged drug release after a single shot. The principle and strategies associated with the long-acting drug delivery technologies are mentioned below:
The technological advancements for the long-acting profile of the drugs (small molecules, peptides, biologics) have led to the rise in the number of novel therapeutics in the market along with the growing number of long-acting molecules in the clinical development pipeline.
Of late, the demand for the availability of long-acting vaginal rings as multipurpose prevention technologies for women is also surfacing. Further, the pharmaceutical industry is extensively focusing on the development of long-acting injectables for protein-based drugs and multidrug therapies.
Moreover, the potential of long-acting injectables is being explored in several debilitating chronic diseases, such as Alzheimer’s, Parkinson’s disease, blindness and HIV. Owing to the advanced LADD technologies, formulation and developmental challenges associated with these complex dosage forms, the reliability of the stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers to address the bottlenecks stemming from conventional treatment options and improve the clinical outcome.
Long-acting Injectable Medications Market report published by Value Market Research, which studies the future outlook of the market.
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the long-acting injectable medications market include Eli Lilly, MedinCell, Zogenix, Alkermes, GSK, Johnson & Johnson, Nanomi, Mapi Pharma, DURECT, Oakwood Labs, Pharmathen, Kashiv BioSciences.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Long-acting Injectable Medications Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/long-acting-injectable-medications-market/download-sampleMarket DynamicsThe high percentage of the population suffering from mental illness like schizophrenia and having a tough time sticking with a treatment plan or cannot take a daily medication is the primary stimulant for the market's growth.
These medications' various benefits like reduced relapse and rehospitalization rates, removal of any potential treatment gaps, and reduced risk of overdose will benefit this market's growth.
Rising healthcare investments and continued research in developing more long-acting injectable psychotropic medications since they can be cost-effective alternatives to traditional drug therapies for treating selective behavioral diseases will boost the market growth.
